This strategy significantly improved therapeutic efficacy while avoiding the systemic inflammation and tissue damage often associated with IFN‐γ administration, highlighting the safety and precision of probiotic‐based tumor immunotherapy. The gene discussed is IFNG; the disease is neoplasm.